Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 14.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell